Management of SLE: -Treat early to prevent organ damage -Taper GC to <5mg/d in the first 6m when feasible -New therapies are promising but still unmet needs in LN, limited global access and lacking data in pregnancy. #EULAR2025 @RheumNow https://t.co/UKK8sTYJD2

• https://x.com/AdelaCastro222/status/1932350268102091208/photo/1
• https://x.com/AdelaCastro222/status/1932350268102091208/photo/1

#EULAR2025 Abstr#OP0035 SGLT2-i and GLP-1 agonist are increasingly used to treat diabetes. Population based study in Canada showed no significant difference in risk of developing an autoimmune rheumatic disease with GLP-1-RA or SGLT2i relative to DPP4i treatment @RheumNow https://t.co/CvPcOqehtl

• https://x.com/Yuz6Yusof/status/1932939395834818772/photo/1

+RCT in #pSjD #Sjogrens #Disease #Leflunomide + #hydroxychloroquine Vs #PBO 2nd study to show this - same group need to know ▶️what pt to use this in ▶️is there diff organ improvements ⬆️#ESSDAI ⬇️RF ⬇️Ig’s Easy to prescribe ?early, mild dx #EULAR2025 @RheumNow @eular_org https://t.co/JE0VyFRXc6

• https://x.com/Janetbirdope/status/1933873925429383674/photo/1
• https://x.com/Janetbirdope/status/1933873925429383674/photo/1
• https://x.com/Janetbirdope/status/1933873925429383674/photo/1
• https://x.com/Janetbirdope/status/1933873925429383674/photo/1

#EULAR2025 Based on the updated EULAR Guidelines on #lupus nephritis, should all patients receive early Combination therapies for remission induction? @RheumNow

In BIODOPT study (RA, PsA, axSpA), disease activity-guided tapering of biologics (incl. biosimilars) maintained QALY (Δ0.008, NS) while lowering biologic costs (Δ€–1,979 [95%CI –3,798;–161]) & total hospital costs (Δ€–1,936 [95%CI –3,753;–119]) over 18mo. Supports https://t.co/CJUpfU2oRA

• https://x.com/synovialjoints/status/1933900613902893138/photo/1

ARIAA study: longer-term data now High-risk ACPA+ clinically suspect arthralgias abatacept for 6mo, then stop altogether Really impressive long-term effect also noting success of APIPPRA, abatacept flicks off some very early RA, at least for a while #EULAR2025 OP0325 @RheumNow https://t.co/AeRrUKPPiK https://t.co/jtynyD0ioO

• https://x.com/drdavidliew/status/1933612907033452725/photo/1
• https://twitter.com/drdavidliew/status/1533099103114211328

EULAR FMF recommendations 2025: still emphasis on colchicine adherence to maximal dose +/- bDMARDs if needed for control +/- csDMARDs for residual chronic MSK involvement new: consider tapering bDMARD if remission >6mo See the treatment algorithm below⬇️ #EULAR2025 @RheumNow https://t.co/Hy6DOKzfUL

• https://x.com/drdavidliew/status/1933786027857998292/photo/1
• https://x.com/drdavidliew/status/1933786027857998292/photo/1

FMF #Recommendations 🔺️Start Colchicine in All (& continue for confirmed pts) 🔺️Single or divided dose, depend on adherence & tolerance 🔺️Max dose 2 mg children, 3 mg adults 🔺️if failure: add IL1i (6 RCT) (2 for IL6i) 🔺️Add c or bDMARd if MSK #EULAR2025 @RheumNow https://t.co/fPyQrLbb6S

• https://x.com/Nellziade/status/1933787923419189744/photo/1

FMF #Recommendations During attack: 🔺️No use of increasing Colchicine 🔺️No use for corticosteroids and opioid 🔺️Use NSAIDs #EULAR2025 @RheumNow https://t.co/jJjWJra7yr

• https://x.com/Nellziade/status/1933787923851457020/photo/1

FMF #Recommendations #Colchicine can be fatal 🔺️Monitor regularly #EULAR2025 @RheumNow https://t.co/VJZYPaBrvE

• https://x.com/Nellziade/status/1933789626692509988/photo/1

FMF #Recommendations #Colchicine can be fatal 🔺️Beware of drug interactions 🔺️Mostly statins in adults 🔺️Macrolides in children #EULAR2025 @RheumNow https://t.co/SYGLpAJXFu

• https://x.com/Nellziade/status/1933794041214148656/photo/1

“That is why this task force continues to say: nothing is better than methotrexate and glucocorticoids to start” - Josef Smolen, on RA treatment #EULAR2025 @RheumNow https://t.co/AbkgWS8tvH

• https://x.com/drdavidliew/status/1933800591379099779/photo/1
• https://x.com/drdavidliew/status/1933800591379099779/photo/1

The key changes for the new 2025 EULAR recommendations on RA treatment #EULAR2025 @RheumNow https://t.co/dp5LnoFdpW

• https://x.com/drdavidliew/status/1933801766572728598/photo/1

URAT1 inhibitors look like the way to go in Gout! Presented in multiple abstracts at #EULAR2025 Pozdeutinurad Ph2 long term safety data chronic gouty arthritis + tophi OP0300 Ph3 RCT of Ruzinurad in hyperuricemia/primary gout OP0302 Ph 2b RCT of SAP-001 Refractory Gout +/-

#EULAR2025 @eular_org update #Recommendations #Rheumatoid #Rx prof Smolen subtle diff between former guidelines MTX+GC 👇 D/C GCs rapidly 👇 If inadequate response 👇 Other csDMARDs are OUT ❎ ✅go to bDMARD or tsDMARD* TsDMARD after safety assessed @RheumNow RecommendatnII https://t.co/yUrLdk6Eg1

• https://x.com/Janetbirdope/status/1933809499317338186/photo/1